アブストラクト
| Title | バセドウ病 |
|---|---|
| Subtitle | 特集 知りたいところをすべて解説! 甲状腺疾患と薬物治療の急所 [代表的な甲状腺疾患の病態と薬物治療] |
| Authors | 内田豊義 |
| Authors (kana) | |
| Organization | 順天堂大学大学院医学研究科 代謝内分泌内科学 |
| Journal | 月刊薬事 |
| Volume | 62 |
| Number | 13 |
| Page | 2495-2499 |
| Year/Month | 2020 / 10 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ●バセドウ病は甲状腺機能亢進症(中毒症)のなかで最も頻度が高い. ●バセドウ病の病態は自己免疫異常に基づく甲状腺におけるホルモン生成過剰であり, 過剰なホルモン生成を抑制する治療が必要である. ●初期治療として遊離サイロキシン(FT4)値<5.0ng/dLではチアマゾール(MMI)15mg/日, FT4値≧5.0ng/dLではMMI 30mg/日もしくはMMI 15mg+ヨウ化カリウム50mgが推奨されている. ●抗甲状腺薬関連副作用が疑われた場合には, 速やかに中止のうえ, 医療機関の受診を勧める. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Tajiri J, ey al : Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med, 150 : 621-624, 1990
- 2) Takata K, et al : Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30mg daily than with 15mg daily. Thyroid, 19 : 559-563, 2009
- 3) 日本甲状腺学会・編 : バセドウ病治療ガイドライン2019. 南江堂, 2019
- 4) Takata K, et al : Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Clin Endocrinol(Oxf), 72 : 845-850, 2010
- 5) Sato S, et al : Comparison of efficacy and adverse effects between methimazole 15mg + inorganic iodine 38mg/day and methimazole 30mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid, 25 : 43-50, 2015
残りの8件を表示する
- 6) Uchida T, et al : Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves' disease : a single-center experience. Endocrine, 47 : 506-511, 2014
- 7) Suzuki N, et al : Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease. Endocr J, 67 : 631-638, 2020
- 8) Okamura K, et al : Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab, 99 : 3995-4002, 2014
- 9) 日本小児内分泌学会/日本甲状腺学会・編 : 小児期発症バセドウ病診療のガイドライン2016(http://jspe.umin.jp/medical/files/gravesdisease_guideline2016.pdf)
- 10) Sato H, et al : Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease : efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab, 24 : 257-263, 2011
- 11) Nordyke RA, et al : Graves' disease. Influence of age on clinical findings. Arch Intern Med, 148 : 626-631, 1988
- 12) Goichot B : Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France : relationships with age, aetiology and hormonal parameters. Clin Endocrinol(Oxf), 84 : 445-451, 2016
- 13) Abraham P, et al : Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev, CD003420, 2010
